VJOncology is committed to improving our service to you

Share this video  

VJOncology is committed to improving our service to you

PROSCA/BLADDR 2022 | Role of genomic profiling in the management of intermediate-risk prostate cancer

Eric Klein, MD, Glickman Urology & Kidney Institute, Cleveland, OH, discusses novel tools for the management of intermediate-risk prostate cancer, including magnetic resonance imaging (MRI) and genomic profiling which can provide additional information to traditional pathological approaches. This interview took place at the Global Congress on Prostate and Bladder Cancer (PROSCA/BLADDR 2022) in Athens, Greece.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter